Sol-Gel Technologies to Present at Upcoming 2021 Solebury Trout Virtual Investor Conference and H.C. Wainwright BioConnect Conference
|Solebury Trout 2021
|Access:||Available on demand at the following Link|
|H.C. Wainwright BioConnect 2021
|Date:||January 11-14, 2020|
|Access:||Available on demand to conference participants.|
About Sol-Gel Technologies
Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for the development of Twyneo (benzoyl peroxide and tretinoin) cream, under investigation for the treatment of acne vulgaris, and Epsolay®, under investigation for the treatment of papulopustular rosacea. The Company’s pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, under investigation for the treatment of palmoplantar keratoderma, and preclinical assets tapinarof and roflumilast. For additional information, please visit www.sol-gel.com.
For further information, please contact:
Chief Financial Officer
Source: Sol-Gel Technologies Ltd.